Drug–gene interactions and the risk of diabetic microvascular complications: A population‐based cohort study
This study provides the first comprehensive assessment of DGIs and diabetic microvascular complications. DGIs involving antithrombotic agents and non-normal CYP2C19 or CYP2D6 metabolizers were significantly linked to higher risks of DKD and DN. These findings underscore the potential of pharmacogenomic-guided prescribing to enhance drug safety.
Authors
- Yalu Wen (ORCID: https://orcid.org/0000-0002-0071-5917)
- Jiao Sun (ORCID: https://orcid.org/0000-0002-8312-2948)
- Changwei Li
- Haibin Li (ORCID: https://orcid.org/0009-0004-2554-5370)
- Jianguang Ji
- Deqiang Zheng
- Xiao Wang
- Ning Li
- Tianmin Ren
Institutions
- University of Auckland (NZ)
- Capital Medical University (CN)
- Lund University (SE)
- University of Macau (MO)
- Beijing Chao-Yang Hospital, Capital Medical University (CN)
- Beijing Automation Control Equipment Institute (CN)
- Skåne University Hospital (SE)
- Beijing Friendship Hospital (CN)
- Beijing Chaoyang Emergency Medical Center (CN)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2026-01-26
- DOI
- https://doi.org/10.1111/dom.70501
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00